We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+19.23%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$140M
AUM Growth
+$21.9M
Cap. Flow
+$4.55M
Cap. Flow %
3.25%
Top 10 Hldgs %
48%
Holding
83
New
9
Increased
22
Reduced
16
Closed
8

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$2.79M
2
IMMU
Immunomedics Inc
IMMU
+$2.7M
3
DERM
Dermira, Inc.
DERM
+$1.44M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.44M
5
NERV icon
Minerva Neurosciences
NERV
+$1.42M

Top Sells

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$2.61M
2
TVRD
Tvardi Therapeutics
TVRD
+$1.75M
3
NVDQ
Novadaq Technologies Inc.
NVDQ
+$747K
4
MTVA
MetaVia Inc
MTVA
+$725K
5
ABEO icon
Abeona Therapeutics
ABEO
+$338K

Sector Composition

Rank Sector Weight
1 Healthcare 80.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
26
Voyager Therapeutics
VYGR
$192M
$1.83M 1.31%
204,808
+133,488
+187% +$1.34M
FOMX
27
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.65M 1.18%
355,667
+30,000
+9% +$134K
ADXS
28
DELISTED
Advaxis Inc
ADXS
$1.6M 1.14%
16,467
+5,000
+44% +$585K
CDTX
29
DELISTED
Cidara Therapeutics
CDTX
$1.56M 1.12%
10,423
– –
NEOS
30
DELISTED
Neos Therapeutics, Inc
NEOS
$1.53M 1.09%
209,873
+114,600
+120% +$865K
SYRE icon
31
Spyre Therapeutics
SYRE
$8.7B
$1.35M 0.96%
13,984
-32
-0.2% -$4.42K
QURE icon
32
uniQure
QURE
$2.77B
$1.26M 0.9%
203,907
– –
JNJ icon
33
Johnson & Johnson
JNJ
$609B
$1.24M 0.89%
9,400
– –
ACHN
34
DELISTED
Achillion Pharmaceuticals
ACHN
$1.22M 0.87%
266,500
+70,000
+36% +$281K
RIGL icon
35
Rigel Pharmaceuticals
RIGL
$750M
$1.21M 0.86%
44,348
-3,000
-6% -$82.1K
XENE icon
36
Xenon Pharmaceuticals
XENE
$6.6B
$1.19M 0.85%
377,695
+38,081
+11% +$149K
NDRM
37
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.13M 0.81%
37,938
+500
+1% +$13K
ARQL
38
DELISTED
Arqule Inc
ARQL
$973K 0.69%
784,508
-22,500
-3% -$24.5K
ELOS
39
DELISTED
Syneron Medical Ltd
ELOS
$941K 0.67%
85,947
– –
ASND icon
40
Ascendis Pharma A/S
ASND
$17.1B
$922K 0.66%
33,214
+15,000
+82% +$396K
SCYX icon
41
SCYNEXIS
SCYX
$42.4M
$907K 0.65%
6,336
+1,562
+33% +$259K
ARGX icon
42
argenx
ARGX
$53.8B
$848K 0.61%
+40,000
New +$833K
BLUE
43
DELISTED
bluebird bio
BLUE
$840K 0.6%
618
-77
-11% -$92.9K
BLRX
44
BioLineRX
BLRX
$12.6M
$828K 0.59%
1,634
-33
-2% -$17K
ZGNX
45
DELISTED
Zogenix, Inc.
ZGNX
$809K 0.58%
55,809
-3,969
-7% -$49.9K
STXS icon
46
Stereotaxis
STXS
$154M
$796K 0.57%
1,372,862
– –
EXAC
47
DELISTED
Exactech Inc
EXAC
$689K 0.49%
23,136
-8,500
-27% -$250K
CGNT
48
DELISTED
Cogentix Medical, Inc.
CGNT
$615K 0.44%
353,482
– –
TNDM icon
49
Tandem Diabetes Care
TNDM
$1.17B
$579K 0.41%
72,429
– –
RCKT icon
50
Rocket Pharmaceuticals
RCKT
$376M
$451K 0.32%
59,284
– –
1
2
3 4

Similar funds

FGWP
Founders Grove Wealth Partners Richmond, Virginia $440M AUM 16.56% 1-Year Est. Return
CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
AWM
Austin Wealth Management Austin, Texas $440M AUM 17.66% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return

DAFNA Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, DAFNA Capital Management held 83 positions worth $140M, up 19% from $118M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management deployed $4.55M of net new capital in Q2 2017, opening 9 new positions and adding to 22 existing holdings. Its largest new stake was SANGAMO THERAPEUTICS INC: 225,000 shares worth $1.98M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was AtriCure, an estimated $2.61M trimmed.

  • DAFNA Capital Management's largest Q2 2017 buy was SANGAMO THERAPEUTICS INC: 225,000 shares worth $1.98M.
  • DAFNA Capital Management added most to Aerie Pharmaceuticals in Q2 2017, an estimated $2.79M increase.
  • DAFNA Capital Management's biggest Q2 2017 reduction was AtriCure, cutting an estimated $2.61M.
  • DAFNA Capital Management fully exited Tvardi Therapeutics in Q2 2017, selling an estimated $1.75M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $140M portfolio in Q2 2017.
  • DAFNA Capital Management opened 9 new positions and closed 8 in Q2 2017.
  • DAFNA Capital Management's portfolio value rose 19% quarter-over-quarter to $140M.

Based on DAFNA Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.